Drug Profile
Seribantumab - Elevation Oncology
Alternative Names: MM-121; SAR-256212Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merrimack Pharmaceuticals
- Developer Elevation Oncology; Merrimack Pharmaceuticals; Sanofi
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Suspended Solid tumours
- Discontinued Gynaecological cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 14 Apr 2023 Safety and efficacy data from a phase II CRESTONE trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 06 Jan 2023 Seribantumab - Elevation Oncology is available for licensing as of 06 Jan 2023. https://elevationoncology.com/our-focus-step-4/# 9378199
- 06 Jan 2023 Suspended - Phase-II for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada, Australia, South Korea, USA (IV) (NCT04383210)